Actively Recruiting

Early Phase 1
Age: 1Year - 21Years
All Genders
NCT05553041

18F-Fluciclovine PET-MRI in High-grade Glioma

Led by Children's Hospital of Philadelphia · Updated on 2025-12-04

30

Participants Needed

1

Research Sites

173 weeks

Total Duration

On this page

Sponsors

C

Children's Hospital of Philadelphia

Lead Sponsor

B

Blue Earth Diagnostics

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes that can occur after treatment.

CONDITIONS

Official Title

18F-Fluciclovine PET-MRI in High-grade Glioma

Who Can Participate

Age: 1Year - 21Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histopathology-proven high-grade glioma (WHO grade III-IV) or diffuse midline glioma (WHO grade IV), or imaging characteristic of diffuse intrinsic pontine gliomas involving ≥2/3 of the pons
  • Measurable disease of at least 1x1 cm
  • Life expectancy greater than 8 weeks
  • Age greater than 1 year and less than 21 years at enrollment
  • For participants without planned surgery: clinical or radiographic suspicion of true progression or pseudoprogression during radiation before the initial post-radiation MRI, or suspicion on first post-radiation MRI
  • For participants with planned surgery: clinical or radiographic suspicion of tumor progression with plan for surgery or biopsy
Not Eligible

You will not qualify if you...

  • Unable to tolerate imaging procedures as judged by investigator or treating physician
  • Pregnant or breastfeeding participants
  • Need for sedation or anesthesia for imaging beyond standard of care
  • Weight less than 8 kilograms
  • Cannot avoid contact with pregnant women or infants for at least 12 hours after injection
  • History of abnormal kidney function or creatinine ≥ CTCAE v5.0 grade 2 at registration
  • Primary tumors of the spinal cord

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

Loading map...

Research Team

M

Mariam Aboian, MD, PhD

CONTACT

N

Nazanin Maleki, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

18F-Fluciclovine PET-MRI in High-grade Glioma | DecenTrialz